NUTX · Nutex Health Inc.
$222.64
-2.37 (-1.05%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$1.51B
Shares
6.85M
Volume · Oct 6
48.51K
Avg daily vol (3M)
150.16K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$225.00
Open$216.35
Day$214.18–225.66
52W close$87.01–225.00
Avg vol 30d161K
Short int1.2M · 18.0% float · 7.5d
Short vol77%
Last earningsAug 7, 2026
DataApr 2022–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held May 1, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$846.72M
Trailing 12 months
Net income (TTM)
$150.33M
Trailing 12 months
Revenue growth YoY
-13.6%
Year over year
Operating margin
43.0%
Trailing 12 months
P / E (TTM)
8.3
Trailing earnings · reciprocal yield 12.0%
FCF yield
18.2%
TTM · current market cap
Return on invested capital
126.4%
Trailing 12 months
Net cash
$165.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+17.1%
Year over year · more shares
Price change (1Y)
+102.0%
Trailing year
Short interest
18.0%
Latest settlement · 7.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+53%
above
Price vs 50-day avg
+19%
above
RSI (14)
65
neutral
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+109%
trailing
YTD return
+37%
this year
Relative strength
+97%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $189 › 200d $147 — 50d above 200d
Institutional flow
Accumulating
1 of 153 funds reported for Sep 30 · net +1 sh shares · +1 new
Insider flow
Distributing
Net -$43.5K over 90 days · 100% sells
Short interest
Rising
18.02% of float · ▲ +6.2% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
153 holders — near 3-yr high, broad support
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
+82%
Y/Y
Gross margin
51%
expanding
EPS growth
+8%
Y/Y
Free cash flow
$245.6M
Buyback
$19.8M
remaining
Balance sheet
$143.1M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+53%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
65
Neutral
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $189 › 200d $147 — 50d above 200d
Institutional flow
Accumulating
1 of 153 funds reported for Sep 30 · net +1 sh shares · +1 new
Insider flow
Distributing
Net -$43.5K over 90 days · 100% sells
Short interest
Rising
18.02% of float · ▲ +6.2% MoM · 7.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
153 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $87
Now $225 · 100%
Range high $225
vs 200-day avg +53%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $89.99M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA attributable to Nutex Health non-GAAP | $147.5M | six months ended June 30, 2026 | — |
| EBITDA non-GAAP | $94.15M | the three months ended June 30, 2026 filing | — |
| Hospital facilities | 27 | as of the filing date | — |
| Total visits at the Hospital Division | 99,704 | six months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUTX
this stock
Nutex Health Inc.
|
$1.51B | +36.7% | +82.4% | — | 18.0% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -6.8% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.6% | +0.9% | 10.0 | 2.5% |
|
FMS
Fresenius Medical Care AG
|
$12.08B | -4.9% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUTX | +5.8% | +16.4% | +108.6% | +6.3% | +36.7% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +4.6% | +15.8% | +97.1% | +4.7% | +23.1% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$25.00M
Spent (derived)
$5.20M
Remaining
$19.80M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.